More testing of the AstraZeneca coronavirus vaccine will be needed to determine its safety and effectiveness, scientists from Oxford University and the World Health Organization have said.
AstraZeneca’s stock fell this week after the company announced interim results of a coronavirus vaccine study on Monday. British pharmaceutical giant AstraZeneca has announced that the vaccine it developed is only 70% effective by combining two different dosing regimens.
A small group of people, all under the age of 55, accidentally received a lower dose of the vaccine followed by a full dose, and a larger group of people received two full doses of the vaccine. The vaccine was found to be 90% effective in the lower dose group, compared to only 62% in the two full vaccine groups.
Some US experts, including the head of the White House’s operation “Warp Speed”, have expressed concern about the different ages of the two groups. Responding to these concerns, Pascal Sorio, AstraZeneca’s CEO, told Bloomberg on Thursday, Nov. 26, that the company will likely launch a new study to test a lower dose of the vaccine.
“The full data will be published in a medical journal for people to check. Data snippets are not a useful way to analyze what’s really going on,” he told CNBC on Friday, Nov. 27.
Other UK government ministers and experts have also backed the AstraZeneca vaccine, saying the final say will eventually be given to drug regulators, who have more information on the late-stage clinical trials of the vaccine.
A survey of Latvian residents about vaccination against Covid-19
On Friday, November 27, the United Kingdom asked its independent drug regulator to evaluate the Covid-19 vaccine, jointly developed by pharmaceutical company AstraZeneca and the University of Oxford, as part of the formal approval process for temporary delivery. This means that the AstraZeneca vaccine could be distributed nationwide by the end of the year.
Read more: VM: Covid-19 vaccines from various manufacturers could be available in Latvia by the end of 2021